Welcome to Finance Insider, Business Insider’s summary of
the top stories of the past 24 hours. Sign up here
to get
the best of Business Insider delivered direct to your
inbox.


Facebook getting back into news
business 

Facebook is
getting back into the business of having employees make decisions
about news organizations
and stories — including about their
credibility — something company leaders including Mark Zuckerberg
have previously renounced.

The company has open job listings for two “news credibility
specialists,” one of which would be required to
be able to speak, read, and write fluently in Spanish. The jobs,
which Facebook listed within the last few weeks, would be
contract positions, rather than full-time, but would be based in
Menlo Park, California, site of Facebook’s headquarters.

Key departure at Tourbillon 

A founding partner
has resigned from the struggling hedge fund Tourbillon Capital
Partners
after six years at the firm.

Advertisement

Amy Zipper, the chief operating officer and president at
Tourbillon Capital, left last week, several people familiar with
the matter said.

Before Tourbillon, Zipper worked at Carlson Capital in business
development, according to her LinkedIn page. Tourbillon’s
founder, Jason Karp, was previously a co-chief investment officer
at Carlson.

Crypto risks abound 

If at first you don’t succeed, try, try, and try again. That
appears to be VanEck’s strategy when it comes to bitcoin-linked
investments.

The asset manager has, for the third
time, filed with the Securities and Exchange
Commission a bitcoin exchange-traded fund, the company announced
earlier this week. It is partnering with blockchain firm SolidX
on the fund.


But one market structure expert is calling the fund’s filing
“laughable.”

More drama at Allergan

A handful of large Allergan shareholders
are privately discussing bringing back former Allergan chief
executive David Pyott
in a chairman role, according to people
familiar with the matter.

Billionaire investor David Tepper’s hedge fund Appaloosa
Management and Senator Investment Group on
Tuesday called on the Botox-maker’s board to split chief
executive and chairman roles at the company which are both
currently held by Brent Saunders. Carl
Icahn has also taken a
stake in the company, according to Bloomberg.

In markets news

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.